Xiaomei Zhang1, Aizhen Lu1, Zhi Li2, Jiali Sun1, Dan Dai1, Liling Qian1. 1. Respiratory Department, Children's Hospital of Fudan University, Shanghai 201102, China. 2. The Children's Hospital of Zhejiang University, School of Medicine, Hangzhou 310052, China.
Abstract
BACKGROUND: Paracrine factors secreted by endothelial progenitor cells (EPCs) are suggested to be responsible, in part, for the improved microvascular development in bronchopulmonary dysplasia (BPD) models. This study aims to investigate the potential role of exosomes derived from EPCs (EPC-EXOs), a component of paracrine secretion, in angiogenesis by mediating the activity of PMVECs exposed to hyperoxia. METHODS: EPCs were isolated from bone marrow of rats. EPC-EXOs were isolated by ExoQuick-TC kits from the conditioned media of EPCs. The PMVECs were divided into three groups, including the normal group, the hyperoxia group (exposed to 85% O2) and the EPC-EXOs treatment group (exposed to 85% O2 and EPC-EXOs with the concentration of 100 µg/mL). The activities of proliferation, migration and tube formation of PMVECs were detected at the endpoint. The mRNA and protein expression levels of VEGF, VEGFR2 and eNOS in different groups were detected by real-time quantitative PCR and western blot. RESULTS: We found EPC-EXOs exhibited a cup or biconcave morphology, with the size ranging from 30 to 150 nm, and positive for the characteristic exosomal surface marker proteins, CD63 and TSG101. Comparing to the control group, Hyperoxic stress impaired the proliferation, migration, and tubule formation of PMVECs, and decreased the expression of endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF), and vascular endothelial growth factor receptor 2 (VEGFR-2) of PMVECs. Comparing to the hyperoxia group, EPC-EXOs treatment enhanced the bioactivity of PMVECs in vitro, and increased the expression of eNOS, VEGF and VEGFR2. CONCLUSIONS: Our data demonstrate EPCs secrete exosomes that have independent angiogenic activity in vitro. This may help explain in part the protective effects of EPCs on hyperoxic injury in the developing lung vasculature and may represent a promising therapeutic strategy for BPD.
BACKGROUND: Paracrine factors secreted by endothelial progenitor cells (EPCs) are suggested to be responsible, in part, for the improved microvascular development in bronchopulmonary dysplasia (BPD) models. This study aims to investigate the potential role of exosomes derived from EPCs (EPC-EXOs), a component of paracrine secretion, in angiogenesis by mediating the activity of PMVECs exposed to hyperoxia. METHODS: EPCs were isolated from bone marrow of rats. EPC-EXOs were isolated by ExoQuick-TC kits from the conditioned media of EPCs. The PMVECs were divided into three groups, including the normal group, the hyperoxia group (exposed to 85% O2) and the EPC-EXOs treatment group (exposed to 85% O2 and EPC-EXOs with the concentration of 100 µg/mL). The activities of proliferation, migration and tube formation of PMVECs were detected at the endpoint. The mRNA and protein expression levels of VEGF, VEGFR2 and eNOS in different groups were detected by real-time quantitative PCR and western blot. RESULTS: We found EPC-EXOs exhibited a cup or biconcave morphology, with the size ranging from 30 to 150 nm, and positive for the characteristic exosomal surface marker proteins, CD63 and TSG101. Comparing to the control group, Hyperoxic stress impaired the proliferation, migration, and tubule formation of PMVECs, and decreased the expression of endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF), and vascular endothelial growth factor receptor 2 (VEGFR-2) of PMVECs. Comparing to the hyperoxia group, EPC-EXOs treatment enhanced the bioactivity of PMVECs in vitro, and increased the expression of eNOS, VEGF and VEGFR2. CONCLUSIONS: Our data demonstrate EPCs secrete exosomes that have independent angiogenic activity in vitro. This may help explain in part the protective effects of EPCs on hyperoxic injury in the developing lung vasculature and may represent a promising therapeutic strategy for BPD.
Authors: A J Bhatt; G S Pryhuber; H Huyck; R H Watkins; L A Metlay; W M Maniscalco Journal: Am J Respir Crit Care Med Date: 2001-11-15 Impact factor: 21.405
Authors: Vivek Balasubramaniam; Anne M Maxey; Danielle B Morgan; Neil E Markham; Steven H Abman Journal: Am J Physiol Lung Cell Mol Physiol Date: 2006-01-27 Impact factor: 5.464
Authors: Hadi Valadi; Karin Ekström; Apostolos Bossios; Margareta Sjöstrand; James J Lee; Jan O Lötvall Journal: Nat Cell Biol Date: 2007-05-07 Impact factor: 28.824
Authors: P J Fracica; M J Knapp; C A Piantadosi; K Takeda; W J Fulkerson; R E Coleman; W G Wolfe; J D Crapo Journal: J Appl Physiol (1985) Date: 1991-12
Authors: Gerry T M Wagenaar; Simone A J ter Horst; Margôt A van Gastelen; Lara M Leijser; Thais Mauad; Pieter A van der Velden; Emile de Heer; Pieter S Hiemstra; Ben J H M Poorthuis; Frans J Walther Journal: Free Radic Biol Med Date: 2004-03-15 Impact factor: 7.376
Authors: Richard D Bland; Lucia M Mokres; Robert Ertsey; Berit E Jacobson; Shu Jiang; Marlene Rabinovitch; Liwen Xu; Eric S Shinwell; Feijie Zhang; Matthew A Beasley Journal: Am J Physiol Lung Cell Mol Physiol Date: 2007-08-17 Impact factor: 5.464